These data suggest STEAP2 expression levels alone are not sufficient to distinguish between Gleason scores due to the similarities in staining, but that it would be a suitable biomarker to distinguish between normal prostate and PCa specimens. Here, STEAP2 is linked to posterior cortical atrophy.